MRTX Mirati Therapeutics, Inc.

+0  (1%)
Previous Close 4.73
Open 4.75
Price To book 1.95
Market Cap 119.08M
Shares 24,939,000
Volume 132,040
Short Ratio 7.02
Av. Daily Volume 161,435

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 combination trial initiated June 2016
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 initiated December 2015. Enrollment ongoing - update due 2H 2017.
Glesatinib (MGCD265)
Non-small cell lung cancer (NSCLC) patients with driver alterations in MET

Latest News

  1. Mirati reports 4Q loss
  2. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
  3. Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference
  4. 5 Stocks Insiders Love Right Now
  5. Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock
  6. Mirati Therapeutics Sets $65M Public Offering
  7. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
  8. Mirati Therapeutics Announces Proposed Public Offering of Common Stock
  9. Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs
  10. How CardConnect Corp (CCN) Stacks Up Against Its Peers
  11. How Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry
  12. Is Mirati Therapeutics, Inc. (MRTX) Going to Burn These Hedge Funds?
  13. Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  14. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016
  15. Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer
  16. 5 Stocks Under $10 That Could Make You a Lot of Money
  17. Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
  18. 7 Stocks Under $10 Making Big Up Moves